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Abstract
Introduction The purpose of this study was to analyze the data
of patients with T-cell large granular lymphocyte (T-LGL)
lymphocytosis associated with inflammatory arthropathy or with
no arthritis symptoms.
Methods Clinical, serological as well as histopathological,
immuhistochemical, and flow cytometric evaluations of
blood/bone marrow of 21 patients with T-LGL lymphocytosis
were performed. The bone marrow samples were also
investigated for T-cell receptor (TCR) and immunoglobulin (IG)
gene rearrangements by polymerase chain reaction with
heteroduplex analysis.
Results Neutropenia was observed in 21 patients,
splenomegaly in 10, autoimmune diseases such as rheumatoid
arthritis (RA) in 9, unclassified arthritis resembling RA in 2, and
autoimmune thyroiditis in 5 patients. T-LGL leukemia was
recognized in 19 cases. Features of Felty syndrome were
observed in all RA patients, representing a spectrum of T-LGL
proliferations from reactive polyclonal through transitional
between reactive and monoclonal to T-LGL leukemia. Bone
marrow trephines from T-LGL leukemia patients showed
interstitial clusters and intrasinusoidal linear infiltrations of
CD3+/CD8+/CD57+/granzyme B+  lymphocytes, reactive
lymphoid nodules, and decreased or normal granulocyte
precursor count with left-shifted maturation. In three-color flow
cytometry (FCM), T-LGL leukemia cells demonstrated CD2,
CD3, and CD8 expression as well as a combination of CD16,
CD56, or CD57. Abnormalities of other T-cell antigen
expressions (especially CD5, CD7, and CD43) were also
detected. In patients with polyclonal T-LGL lymphocytosis, T
cells were dispersed in the bone marrow and the expression of
pan-T-cell antigens in FCM was normal. Molecular studies
revealed TCRB and TCRG gene rearrangements in 13 patients
and TCRB, TCRG, and TCRD in 4 patients. The most frequently
rearranged regions of variable genes were Vβ-Jβ1, Jβ2 and Vγ If
Vγ10-Jγ. Moreover, in 4 patients, additional rearrangements of IG
kappa and lambda variable genes of B cells were also observed.
Conclusion RA and neutropenia patients represented a
continuous spectrum of T-LGL proliferations, although
monoclonal expansions were most frequently observed. The
histopathological pattern and immunophenotype of bone
marrow infiltration as well as molecular characteristics were
similar in T-LGL leukemia patients with and without arthritis.
aCL = anticardiolipin antibody; ANA = antinuclear antibody; ARA = American Rheumatism Association; BD = Becton Dickinson, San Jose, CA, USA; 
CCP = anticyclic citrullinated peptide (antibody); CSA = cyclosporine A; ELISA = enzyme-linked immunosorbent assay; FCM = flow cytometry; FS 
= Felty syndrome; G-CSF = granulocyte-colony stimulating factor; IGH = immunoglobulin heavy chain; IGK = immunoglobulin kappa; IGKV = immu-
noglobulin kappa variable; IGL = immunoglobulin lambda; IGLV = immunoglobulin lambda variable; INF-γ = interferon-gamma; LGL = large granular 
lymphocyte; MTX = methotrexate; NK = natural killer; PCR = polymerase chain reaction; PR = partial response; RA = rheumatoid arthritis; RF = rheu-
matoid factor; TCR = T-cell receptor; T-LGL = T-cell large granular lymphocyte; TNF-α = tumor necrosis factor-alpha; WHO = World Health 
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Introduction
The etiology of such abnormalities as lymphocytosis, neutro-
penia, and arthropathy diagnosed either by a rheumatologist or
a hematologist often remains obscure. These clinical findings
may be associated with the presence of circulating T-cell large
granular lymphocytes (T-LGLs) [1-3]. LGL disorders comprise
a spectrum of polyclonal, oligoclonal, or monoclonal expan-
sions [4], which arise mostly from mature, activated cytotoxic
T lymphocytes (T-LGL) CD3+/CD8+/CD57+/CD16+ and less
often from natural killer cells (NK-LGL) CD3-
/CD2+/CD56+/CD16+ [5]. Clinically pronounced monoclonal
proliferation of T-LGLs with bone marrow and spleen infiltra-
tion is diagnosed as T-LGL leukemia, a rare, indolent, chronic
disorder with characteristic features such as mild lymphocyto-
sis, neutropenia, and anemia. They may be autoimmune by
nature or result from a T-cell-mediated suppressor effect on
hemopoesis [6,7]. The T-LGL leukemia diagnosis is confirmed
by monoclonal T-cell receptor (TCR) gene rearrangement
detected in abnormal CD3+/CD57+ cell populations [5,6]. An
interesting feature of T-LGL leukemia is its strong association
with a number of autoimmune disorders and immunological
abnormalities, most common in patients with rheumatoid
arthritis (RA) (30% of patients), which usually precedes or
develops concurrently with the hematological process [8-10].
Patients with T-LGL leukemia and accompanying RA closely
resemble patients with Felty syndrome (FS) in clinical presen-
tation: neutropenia, RA, variable splenomegaly, and immuno-
genetic findings such as a high prevalence of HLA-DR4
[11,12]. Moreover, monoclonal T-LGL lymphocytosis may be
found in up to one third of FS patients [11,13-15]. Burks and
Loughran [7] suggest that these two entities represent vari-
ants of the same clinicopathologic process. The aim of the
present study was to perform an extensive clinical, histopatho-
logical, flow cytometric as well as genetic evaluation of 21
patients with T-LGL lymphocytosis associated with inflamma-
tory arthropathy or with no arthritis symptoms. Our results
demonstrate that patients with RA and neutropenia represent
a continuous spectrum of T-LGL proliferations although mon-
oclonal expansions are observed most frequently. The his-
topathological pattern and immunophenotype of the bone
marrow infiltration as well as molecular characteristics were
similar in T-LGL leukemia patients with and without arthritis.
Materials and methods
A group of 21 patients with lymphocytosis and neutropenia,
including several with arthropathy and splenomegaly, was
enrolled in this study. Written informed consent was obtained
from all of the patients, and the study was approved by the
local bioethical committee of the Institute of Hematology and
Transfusion Medicine in Warsaw. Complete blood count with
manual differential analysis of blood cells was performed in all
cases. Blood smears stained with May-Grünwald-Giemsa
were examined for the presence of large granular
lymphocytes.
Features of articular disease were defined in terms of duration
and diagnosis (American Rheumatism Association [ARA] cri-
teria for diagnosis of RA) [16]. In some patients, tests were
done for rheumatoid factor (RF) (nephelometry), anticyclic cit-
rullinated peptide (CCP) antibodies and anticardiolipin anti-
bodies (aCLs) (enzyme-linked immunosorbent assay, ELISA),
antinuclear antibodies (ANAs) (Hep2 cells), and cytoplasmic
and perinuclear antineutrophil cytoplasmic antibodies (ELISA),
depending on the clinical presentation of the patient.
Trephine biopsies of all 21 patients were histopathologically
examined. They were fixed in Oxford fixative, routinely proc-
essed, and stained with hematoxylin and eosin. Immunohisto-
chemical studies were done (EnVision™ Detection Systems)
(Dako Denmark A/S, Glostrup, Denmark) (DAKO) using the
following mono- and polyclonal antibodies: CD3, myeloperox-
ydase, hemoglobin (polyclonal), CD20 (L26), CD8 (C8/144B)
(DAKO) and CD4 (4B12), CD57 (NK-1), and granzyme B
(11F1) (Novocastra, now part of Leica Microsystems, Wetzlar,
Germany). Positive and negative controls were included.
Immunophenotyping of peripheral blood lymphocytes was per-
formed in 15 patients with a three-color FACScalibur cytome-
ter (flow cytometry, FCM) (Becton Dickinson, San Jose, CA,
USA) (BD) and analyzed by CellQuest software (BD). Lym-
phocytes were treated with monoclonal antibodies against
CD45 and HLA-DR; pan-B antigen: CD19 (BD); pan-T anti-
gens: CD3 (DAKO), CD2, CD4, CD5, CD7, CD8, CD43,
TCRαβ, and TCRγδ (BD); and NK-specific markers: CD16
(DAKO), CD56 (BD), CD57 (Sigma-Aldrich, St. Louis, MO,
USA), and human IL-2 Rα receptor CD25 (BD). Isotype con-
trols were used.
TCR genes as well as immunoglobulin heavy-chain (IGH) and
kappa (IGK) and lambda (IGL) light-chain gene rearrange-
ments were tested in 19 patients following the BIOMED-2 pro-
tocol [17]. DNA was isolated from blood/bone marrow
mononuclear cells with the column method (Qiagen, Hilden,
Germany) after Ficoll separation. TCRBV-TCRJ  gene rear-
rangements were tested using 23 forward and 9 reverse prim-
ers (Vβ-Jβ1, Jβ2) and 23 forward and 4 reverse primers for
regions Vβ-Jβ2 and 2 forward and 13 reverse primers for
regions Dβ1, Dβ2-Jβ. TCRG gene rearrangements were tested
using 2 forward and 2 reverse primers for regions Vγ If, Vγ10-Jγ
and 2 forward and 2 reverse primers for regions coding Vγ9,
Vγ11-Jγ. TCRD gene rearrangements were tested using 7 for-
ward and 5 reverse primers for regions coding Vδ, Dδ2-Jδ, Dδ3.
The IGH gene rearrangement test consisted of three multiplex
polymerase chain reaction (PCR) tubes with 27 forward and 5
reverse primers, IGK tests consisted of 2 multiplex PCR tubes
with 13 forward and 3 reverse primers, and the IGL test con-
sisted of 1 multiplex PCR tube with 6 forward and 2 reverse
primers. PCR products underwent heteroduplex analysis
(95°C for 5 minutes and 4°C for 60 minutes) and were sepa-
rated using electrophoresis on polyacrylamide gel andAvailable online http://arthritis-research.com/content/10/3/R55
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visualized by ethidium bromide. Cytogenetic studies on bone
marrow aspirate samples of 7 patients were performed using
a G-banding technique, and the results were analyzed accord-
ing to International System for Human Cytogenetic Nomencla-
ture (1995). The T-LGL leukemia diagnosis was made
according to the World Health Organization (WHO) classifi-
cation [6] in cases with monoclonal LGL lymphocytosis
CD3+/CD57+/TCRαβ+/γδ+ of more than 6 months in duration.
Cases with circulating LGLs of greater than 2 × 109/L in
peripheral blood as well as patients with leucopenia and
smaller expansions of LGL were included. The diagnosis of T-
LGL lymphocytosis in 21 patients was based on blood and
bone marrow tests, including immunophenotypic and molecu-
lar studies.
Results
Clinical and laboratory characteristics
The clinical symptoms and hematological data of 21 patients
are summarized in Tables 1 and 2. The median age was 55.7
years (range 28 to 84 years). For all patients, the cell count
detected in routine blood tests was abnormal. Lymphocytosis
ranged from 0.8 to 34.5 × 109/L and persisted for at least 6
months. On cytological examination of blood smears, lym-
phocytes consisted mainly of LGLs. Neutropenia
(<1.5 × 109/L) was the predominant hematological abnormal-
ity in 21 patients and was severe in 12 (<0.5 × 109/L). Several
patients had other cytopenias: leucopenia (white blood cells
<4.5 × 109/L) was diagnosed in 9 patients, anemia (hemo-
globin <10 g/dL) in 5 patients, and thrombocytopenia (plate-
lets <150 × 109/L) in 9 patients.
Eleven patients with articular disease demonstrated various
degrees of inflammatory arthropathy. Nine patients had long-
lasting (5 to 43 years) RA with erosions and fulfilled the ARA
diagnosis criteria. RA preceded the onset of hematological
abnormalities by 3 to 43 years. All of these patients had posi-
tive RF (RF-IgM), CCP antibodies, and ANAs as well as poly-
clonal hypergammaglobulinemia and were diagnosed as FS
due to neutropenia and/or splenomegaly [18]. Two patients (8
and 9) had unclassified arthritis that resembled RA but did not
fulfill the ARA criteria for this diagnosis. Their articular disease
was symmetrical and peripheral with arthralgia, stiffness, peri-
odic swelling, and subchondral cysts on ultrasonography, but
no erosions. In both patients, aCLs were detected. ANAs were
positive in patient 8, and antibodies to double-stranded DNA,
RF-IgM, and anti-CCP were positive in patient 9. Both patients
presented with splenomegaly, recurrent infections due to
severe neutropenia, and skin lesions. In one (patient 8),
arthropathy was observed 7 years before hematological
abnormalities whereas in the other (patient 9) it appeared after
a 17-year history of leucopenia, LGL lymphocytosis, and neu-
tropenia. In 10 patients, there were no symptoms of arthritis or
serological abnormalities except polyclonal hypergammaglob-
ulinemia in 7 patients, aCL in 1 patient, and RF in 1 patient.
Cytoplasmic antineutrophil antibodies were positive in 1 of 10
tested patients (patient 12).
Four patients had constitutional symptoms such as fatigue and
weight loss. Ten patients demonstrated splenomegaly (>14
cm splenic axis in ultrasonography). Three had recurrent bac-
terial infections of the respiratory tract (sinusitis, bronchitis,
and pneumonia) and 1 patient had a foot abscess. In 3
patients, skin lesions in the form of macular pigmented skin
rash were observed. Autoimmune thyroiditis was documented
in 5 patients.
Bone marrow morphology and immunohistochemistry
Morphological and immunohistochemical bone marrow char-
acteristics are summarized in Table 3. The bone marrow was
hypercellular in 11 patients, normocellular in 5 patients, and
hypocellular in 5 patients. Sections stained with monoclonal
antibodies revealed interstitial infiltrates of small lymphocytes
with slightly irregular nuclei and scanty cytoplasm, which
formed small clusters and aggregates in all patients with TCR
gene rearrangements. Moreover, in 14 of them, the infiltrates
also had a clear intrasinusoidal linear component (Figure 1a).
These infiltrations were subtle and difficult to notice on stand-
ard hematoxylin and eosin stain. T cells were CD3+, CD8+,
granzyme B+, and CD4- in 16 patients (Figure 1b). Three
patients had different phenotypes of T cells: CD3+/CD4-
/CD8-, CD3+/CD4+/CD8-, and CD3+/CD4+/CD8+. CD57
staining gave variable results and was positive in 12 patients,
positive in only some T cells in 5 patients, and negative in 2
patients. In two cases (patients 10 and 11) with polyclonal T-
LGL lymphocytosis, CD3+CD8+CD57+/-/granzyme B+/- lym-
phocytes were dispersed in the bone marrow and did not form
clusters or intravascular infiltrations (Figure 1c). Reactive inter-
trabecular lymphoid nodules were detected in 14 of 21 exam-
ined patients (Figure 1d). B cells in the center of these nodules
expressed CD20 and, in 2 cases, formed germinal centers
(Figure 1e). They were surrounded by small CD3+ T lym-
phocytes expressing predominantly CD4+  and only a few
CD8+ cells. Myeloperoxydase stain showed decreased granu-
locyte precursors with left-shifted maturation in 12 patients,
normal in 7 patients, and increased in 2 patients (Figure 1f).
Red cell precursors revealed normal maturation. In most
cases, the megakaryocyte count and their morphology were
normal.
Flow cytometry immunophenotyping
The results of lymphocyte surface marker analysis performed
in 15 patients are summarized in Table 3. The typical immu-
nophenotype of T-LGL leukemia cells was CD45+bright,
CD2+bright, CD3+bright, CD4-, CD8+bright, CD25-, and
CD43+weaker. CD5 and CD7 expression was variable (bright,
dim, or negative) on all or part of the T-LGL leukemia cells,
whereas in 3 cases lymphocytes showed an absence of both
antigens. In all studied cases, T-LGL leukemia cells expressed
a slightly weaker level of CD43 as compared with normalArthritis Research & Therapy    Vol 10 No 3    Prochorec-Sobieszek et al.
Page 4 of 12
(page number not for citation purposes)
expression of CD43+higher on T lymphocytes. Aberrant expres-
sion of CD3 was found in only 1 patient. All tested cases
expressed CD16. However, 10 cases showed only partial
expression of this antigen, with 20% to 95% of the T-LGL
leukemia cells showing reactivity. Lack of CD56 expression
was noted in 10 cases; in 2 cases, CD56 was expressed in
more than 50% of the T-LGL leukemia cells. In 10 cases, 20%
to 100% of the T-LGL leukemia cells showed expression of
CD57, whereas 3 cases were negative. HLA-DR was
expressed in all tested cases in varying percentages. TCR pro-
teins were tested in 10 cases, 8 of them expressing TCRαβ
and 2 TCRγδ (Figure 2). Patient 5 with TCRγδ protein expres-
sion had two immunophenotypically different populations of T-
LGL leukemia cells and is the subject of a separate report. In
Table 1
Basic clinical data, details of arthropathy, serologic findings, and therapy
Case Age/gender Clinical presentation 
and arthropathy
Spleen, mm ANA RF IgM, IU/mL ANCA CCP aCL HP Therapy
1 84/F RA (43 y), BCC (7 m), 
AITD, weight loss
120 1/160 423 Neg Pos Pos Yes Corticosteroids
2 56/F RA (10 y), BCC (6 y), 
amyloidosis AA
115 1/160 320 Neg Pos ND Yes Corticosteroids
3 75/F RA (7 y), BCC (2 y), 
weight loss
180 1/160 125 Neg Pos ND Yes Corticosteroids
4 36/F RA (18 y), BCC (4 y), 
AITD
187 1/160 335 Neg Pos ND Yes Corticosteroids/M
TX
5 58/F RA (32 y), BCC (1 y), 
AITD
95 1/160 97 Neg Pos ND Yes Corticosteroids/M
TX
6 74/M RA (10 y), BCC (3 y) 150 1/320 325 Neg Pos Pos Yes Unknown
7 57/M RA (10 y), BCC (3 y) 200 1/160 320 ND Pos ND Yes Corticosteroids/M
TX
8 52/F UA (12 y), BCC (3 y), 
recurrent infections, 
skin lesions
160 1/320 Neg Neg ND Pos Yes Corticosteroids
9 68/F BCC (17 y), UA (2 y), 
recurrent infections, 
skin lesions
185 1/80 dsDNA 97 Neg Pos Pos Yes G-CSF/MTX
10 51/F RA (8 y), rheumatoid 
nodules, BCC (3 y)
185 1/160 450 Neg Pos Pos Yes MTX/CSA/Cortico
steroids
11 35/F RA (5 y), BCC (6 m) 86 1/320 640 ND Pos ND Yes Corticosteroids
12 50/F BCC (6 m) 113 1/80 29 Pos/Neg Neg Pos Yes MTX
13 28/F BCC (10 y), AITD 103 Neg ND ND ND ND Yes None
14 47/F BCC (1 y), AITD 130 ND ND ND ND ND No Corticosteroids/M
TX
15 55/F BCC (1 y), 
glomerulonephritis (10 
y)
200 ND ND ND ND ND Yes MTX/Corticosteroi
ds
16 52/F BCC (2 y) 115 Neg Neg Neg ND ND Yes CSA/G-CSF
17 54/M BCC (3 y) 145 Neg Neg Neg ND ND No Unknown
18 70/M BCC (1 y), weight loss, 
skin lesions
115 ND ND ND ND ND No MTX/Corticosteroi
ds
19 66/F BCC, recurrent 
infections, weight loss 
(10 y)
120 Neg Neg ND ND ND Yes Unknown
20 69/F BCC (6 y) 125 Neg Neg ND ND ND Yes Unknown
21 33/F BCC (6 m) 150 1/80 160 ND ND ND Yes CSA
aCL, anticardiolipin antibody; AITD, autoimmune thyroiditis; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; BCC, 
blood cell count abnormalities; CCP, anticyclic citrullinated peptide antibodies; CSA, cyclosporine A; dsDNA, double-stranded DNA; F, female; 
G-CSF, granulocyte-colony stimulating factor; HP, polyclonal hipergammaglobulinemia; m, months of observation; M, male; MTX, methotrexate; 
ND, not done; Neg, negative; Pos, positive; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, unclassified arthritis; y, years of observation.Available online http://arthritis-research.com/content/10/3/R55
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Table 2
Hematological data and T-cell receptor and immunoglobulin gene rearrangements
Case Hemoglobin, 
g/dL








Platelet count, × 
109/L
TCR and IG gene 
rearrangements
1 14.1 2.4 0.31 2.0 1.4 204 Vβ-Jβ2, Vγ If, Vγ10-Jγ, 
Vγ9, Vγ11-Jγ
2 14.6 7.6 0.22 7.1 4.6 148 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Vγ If, 
Vγ10-Jγ
3 11.3 1.6 0.05 1.3 0.9 103 ND
4 8.2 15.7 1.45 12.9 11.4 381 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Dβ1, 
Dβ2-Jβ, Vγ If, Vγ10-Jγ, 
Vγ9, Vγ11-Jγ Vκ-Jκ
5 13.4 9.2 1.5 6.6 4.1 230 Dβ1, Dβ2-Jβ, Vγ If, Vγ10-
Jγ, Vδ, Dδ2-Jδ, Dδ3 
(biclonal)
6 10.6 2.4 0.31 1.6 1.1 234 Vβ-Jβ1, Jβ2, Dβ1, Dβ2-Jβ, 
Vγ If, Vγ10-Jγ
7 14.1 1.1 0.15 0.8 0.75 113 Vγ If, Vγ10-Jγ, Vγ9, Vγ11-
Jγ, Vδ, Dδ2-Jδ, Dδ3 Vκ, 
intron-Kde; Vλ-Jλ
8 11.4 2.6 0.39 1.8 0.9 100 Vβ-Jβ1, Jβ2, Dβ1, Dβ2-Jβ
9 11.9 0.9 0.09 0.8 0.5 98 Vβ-Jβ1, Jβ2, Vβ-Jβ2 Vκ-
Jκ; Vκ, intron-Kde 
(biclonal or biallelic); 
Vλ-Jλ
10 12.1 1.3 0.14 0.8 0.3 112 No rearrangement
11 10.8 1.2 0.06 1.02 0.4 321 No rearrangement
12 9.7 8.7 0.12 7.9 7.1 192 Vβ-Jβ1, Jβ2, Dβ1Dβ2-Jβ 
(biclonal or biallelic), 
Vγ If Vγ10-Jγ
13 12.2 8.52 0.72 6.9 6.5 301 Vβ-Jβ1, Jβ2, Dβ1, Dβ2-Jβ, 
Vγ If, Vγ10-Jγ (biclonal 
or bliallelic)
14 7.8 7.7 0.8 6.3 4.5 21 ND
15 10.9 17.8 0.71 16.4 11.8 285 Vβ-Jβ1, Jβ2, Dβ1, Dβ2-Jβ 
(biclonal or biallelic), 
Vγ If, Vγ10-Jγ, Vγ9, Vγ11-
Jγ (biclonal or biallelic) 
Vκ-Jκ
16 13.0 8.9 0.35 8.5 4.6 200 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Dβ1, 
Dβ2-Jβ, Vγ If, Vγ10-Jγ, 
Vγ9, Vγ11-Jγ
17 14.4 2.65 0.10 2.4 2.0 115 Dβ1, Dβ2-Jβ
18 14.9 36.4 0.66 34.5 26.9 57 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Dβ1, 
Dβ2-Jβ, Vγ9, Vγ11-Jγ, Vδ, 
Dδ2-Jδ, Dδ3 (biclonal or 
biallelic)
19 10.2 9.6 0.85 8.4 5.7 154 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Vγ If, 
Vγ10-Jγ Vγ9, Vγ11-Jγ, Vδ, 
Dδ2-Jδ, Dδ3
20 9.5 8.5 0.52 7.2 5.4 220 Vβ-Jβ1, Jβ2, Vβ-Jβ2, Vγ If, 
Vγ10-Jγ
21 4.5 4.5 0.74 3.7 2.1 228 Vβ-Jβ1, Jβ2, (biclonal or 
biallelic), Vβ-Jβ2 Vγ If, 
Vγ10-Jγ (biclonal or 
biallelic)
IG, immunoglobulin; LGL, large granular lymphocyte; ND, not done; TCR, T-cell receptor; WBC, white blood cells.Arthritis Research & Therapy    Vol 10 No 3    Prochorec-Sobieszek et al.
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Table 3
Bone marrow morphological and immunophenotypic characteristics
Number Cellularity Type of infiltrate Percentage of LGLs Phenotype by IHC Phenotype by flow 
cytometry
RCP GP Meg LN
1 N IC, IVL 35 3+, 4-, 8+, 57+, gr B+ 2+, 3+, 4-, 5+, 7+/-↓, 8+, 
16+/-, 56-, 57+
ND ,  L S MN +
2 N IC, IVL 30 3+, 4-, 8+, 57+, gr B+/- ND N I, LSM N +
3NI C 5 0 3 +, 4-, 8+, 57+/-, gr B+ 2+, 3+, 4-, 5+/-↓, 7+, 8+, 
16+/-, 56-, 57+, TCRαβ+, 
TCRγδ-
ND ,  L S MN -
4 I IC, IVL 58 ND 2+, 3+, 4-, 5-, 7+/-↓, 
8+,16+/-, 56-, 57-, 43+↓, 
25-, TCRαβ+, TCRγδ-, 
HLA-DR+/-
DN ,  L S MN +
5a DI C ,  I V L 1 53 +, 4-, 8-, 57+, gr B+/- 2+, 3+, 4-, 5+/-↓, 7+, 8-, 
16+/-, 56+/-, 57-, 43+, 25-, 
TCRαβ-, TCRγδ+, HLA-
DR+ and 2+, 3+, 4-, 5-, 7+, 
8+/-, 16+, 56+/-, 57+, 43+, 
25-, TCRαβ-, TCRγδ+, 
HLA-DR+
NN ,  L S MN +
6II C 4 0 3 +, 4-, 8+, 57+, gr B+ ND N D, LSM N +
7II C 8 0 3 +, 4-, 8-/+, 57+/-, gr B+ 2+, 3+, 4-, 5+, 7+/-↓, 8+/-, 
16+/-, 56+/-, 57+, TCRαβ-, 
TCRγδ+, HLA-DR+/-
ND ,  L S MN -
8 N IC, IVL 25 3+, 4+, 8-, 57+, gr B+ ND N D, LSM N +
9 I IC, IVL 35 3+, 4+, 8+, 57+, gr B+/- ND N D, LSM D +
10 I DI 15 3+, 4-, 8+, 57+/-, gr B+/- 2+, 3+, 4-, 5+, 7+, 8+, 16+/-, 
56+/-, 57+/-, HLA-DR-/+
NI ,  L S MN+
11 D DI 15 3+, 4-, 8+, 57+/- gr B+/- 2+, 3+, 4-, 5+, 7+, 8+, 16+/-, 
56-, 57+/-
ND ,  L S MN -
12 I IC, IVL 50 3+, 4-, 8+, 57+, gr B+ 2+, 3+, 4-, 5+/-↓, 7+, 8+, 
16+, 56+/-, 57+/-, 25-, HLA-
DR+/-
ND ,  L S MN +
13 D IC, IVL 20 3+, 4-, 8+, 57+, gr B+ 2+, 3+, 4-, 5+, 7-↓, 8+, 16+, 
56-, 57+/-, 43+↓, 25-, 
TCRαβ+, TCRγδ-, HLA-
DR+
DN ,  L S MN -
14 I IC 20 3+, 4-, 8+, 57-, gr B+/- 2+, 3+, 4-, 5+, 7+/-↓, 8+, 
16+/-, 56-, 57-, 25-, 
TCRαβ+, TCRγδ-, HLA-
DR+/-
DN ,  L S MN -
15 I IC, IVL 20 3+, 4-, 8+, 57-, gr B+ 2+, 3+, 4-, 5-↓, 7-↓, 8+, 
16+/-, 56-, 57-, 43+↓, 25-, 
TCRαβ+, TCRγδ-, HLA-
DR+/-
ND ,  L S MN +
16 N IC, IVL 25 3+, 4-, 8+, 57+, gr B+/- 2+, 3+, 4-, 5-↓, 7-↓, 8+, 
16+/-, 56-, TCRαβ+, 
TCRγδ-, HLA-DR+
ND ,  L S MN +
17 D IC, IVL 60 3+, 4-, 8+, 57+, gr B+ 2+, 3+, 4-, 5-↓, 7-↓, 8+ ND ,  L S MN -
18 I IC, IVL 25 3+, 4-, 8+, 57+/-, gr B+ 2+, 3+/-↓, 4-, 5+/-↓, 7+/-↓, 
8+, 16+, 56-, 57+/-, 43+↓, 
25-, TCRαβ+, TCRγδ-, 
HLA-DR+
NN ,  L S MN -
19 I IC 30 3+, 4-, 8+, 57+/-, gr B+ 2+, 3+, 4-, 5+, 7+/-↓, 8+, 
16+, 56-, 57+/-, 25-, 
TCRαβ+, TCRγδ-, HLA-
DR+
DN ,  L S MD +
20 D IC, IVL 25 3+, 4-, 8+, 57+, gr B+ ND D N, LSM N +
21 I IC, IVL 25 3+, 4-, 8+, 57+, gr B+ ND N D, LSM N +
aTwo cell populations.
Expression of antigens: -, lack of antigen expression; +/-, partial expression varying from 20% to 95% of cells; +, expression of antigens on 100% 
of cells; ↓, abnormal expression (dim, partial, or negative expression) and CD43 (weaker level). D, decreased; DI, dispersed; GP, granulocyte 
precursors; gr B, granzyme B; I, increased; IC, interstitial clusters; IHC, immunohistochemistry (phenotype in expression of CD markers); IVL, 
intravascular lymphocytes; LGLs, large granular lymphocytes; LN, lymphoid nodules; LSM, left-shifted maturation; Meg, megakaryocyte; N, normal; 
ND, not done; RCP, red cell precursors; TCR, T-cell receptor.Available online http://arthritis-research.com/content/10/3/R55
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analyzed cases both normal reactive peripheral blood CD57+
T lymphocytes and CD57+ T-LGL leukemia cells were found.
In the former no loss of expression of any pan-T antigens was
observed, in the latter typical abnormalities of pan-T-cell anti-
gens were noted. In patients 10 and 11, with no rearrange-
ment of the TCR genes, T-LGLs were characterized by normal
expression of T-cell antigens.
Genetic analysis
The detailed results of TCR  gene rearrangement tests are
summarized in Table 2. Two patients (patients 10 and 11) had
no rearrangement in TCR genes consistent with polyclonal
lymphocytosis (Figure 3a). Patient 7, apart from monoclonal
TCR rearrangement in the delta chain, showed a weak mono-
clonal product in the TCRG Vγ9, Vγ11-Jγ region in polyclonal
background (Figure 3b). Clearly monoclonal TCR gene rear-
rangements were detected in 16 patients (Figure 3c). Three
patients had rearrangements in genes coding beta chains, 10
showed clonality in genes coding beta and gamma chains, and
3 had rearrangement in genes coding beta, gamma, and delta
chains. The spectrum of TCR gene rearrangements was quite
variable, although there were some repeated uses observed.
The most frequently rearranged regions of variable genes were
Vβ-Jβ1, Jβ2 (13 patients) and Vγ If Vγ10-Jγ (13 patients). Moreo-
ver, 4 patients (patients 4, 7, 9, and 15) also presented rear-
rangements of immunoglobulin kappa variable (IGKV) or
lambda variable (IGLV) genes. Classic cytogenetic tests with
GTG banding of the bone marrow cells were performed in 7
patients (patients 1, 4, 9, 12, 13, 15, and 18) and revealed a
normal karyotype.
Therapy and follow-up
Various therapeutic approaches were used as presented in
Table 1. The T-LGL leukemia treatment corrected cytopenias:
neutropenia in 14 and anemia in 4 patients as well as symp-
toms of arthritis. Therapy included methotrexate (MTX),
cyclosporine A (CSA), corticosteroids, and granulocyte-col-
ony stimulating factor (G-CSF). The overall response rate to
therapy in our series was 50%. None of the treated patients
achieved complete hematologic remission. In 8 patients with
T-LGL leukemia, low oral doses of MTX (7.5 to 15 mg weekly)
for 1 to 42 months (median duration 14.4 months) were given.
Six patients received concomitant prednisone (5 to 40 mg
daily) or G-CSF. In 5 patients (patients 4, 9, 12, 15, and 18),
the response was partial (PR), which was defined as improve-
ment of the blood cell count by more than 50%. Two patients
received oral CSA therapy (2 and 3 mg/kg daily) for 15 and 21
months, and, in both, PR was achieved. One of them received
a combination of CSA and G-CSF therapy. Prednisone alone
(5 to 10 mg daily) was given to 4 patients for 12 to 34 months
(median duration 20 months) as a continuation of previous
arthritis treatment. No response was noted in these patients,
but anemia and recurrent infections as well as RA were con-
trolled. In all of the patients, arthritis responded well to the
treatment. Two patients with FS and polyclonal T-LGL lym-
phocytosis were treated with a combination of MTX, CSA, and
prednisone as well as prednisone alone. The first patient
achieved PR, and the second achieved only a transient
improvement of neutropenia. During 1 to 17 years of follow-up,
hematologic disease remained indolent in the majority of
patients, with the exception of 2 patients. Patient 14 died due
to severe bacterial pneumonia complicated by sepsis, dissem-
inated intravascular coagulation, and myocardial infarction. An
autopsy was not performed but death most probably was
related to T-LGL leukemia-associated neutropenia. Patient 2
died of a cause unrelated to disease: secondary renal amy-
loidosis (Amyloid A), a complication of long-lasting RA.
Figure 1
Histopathological features of bone marrow in patients with arthritis and  T-cell large granular lymphocyte (T-LGL) lymphocytosis Histopathological features of bone marrow in patients with arthritis and 
T-cell large granular lymphocyte (T-LGL) lymphocytosis. (a) Patient 1 
with rheumatoid arthritis (RA) and T-LGL leukemia. Staining for CD57 
demonstrates intrasinusoidal linear arrays and interstitial clusters of T 
cells (EnVision stain, ×100). (b) Granzyme B highlights cytotoxic gran-
ules in these cells (EnVision stain, ×200). (c) Patient 10 with polyclonal 
T-LGL lymphocytosis. Staining for CD8 shows dispersed T cells (EnVi-
sion stain, ×200). (d) Patient 9 with unclassified arthritis, T-LGL leuke-
mia, and IGKV and IGLV gene rearrangements. CD3 staining shows 
interstitial and nodular infiltration of T cells (EnVision stain, ×100). (e) 
Patient 9. The lymphoid nodule contains few CD20+ B cells (EnVision 
stain, ×200). (f) Patient 7 with RA and T-LGL leukemia. A decreased 
count of granulocytic precursors (myeloperoxydase+) is shown (EnVi-
sion stain, ×200). IGKV, immunoglobulin kappa variable; IGLV, immu-
noglobulin lambda variableArthritis Research & Therapy    Vol 10 No 3    Prochorec-Sobieszek et al.
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Discussion
The pathogenic relationship between RA and various T-LGL
proliferations that are a spectrum of disorders from reactive
expansion of 'normal' CD8+ cytotoxic T lymphocytes through
chronic oligoclonal or monoclonal LGL lymphocytosis to clini-
cally overt T-LGL leukemia is unclear [4]. This association is
considered rare, perhaps due to underdiagnosis of T-LGL pro-
liferations as the cause of neutropenia in patients with RA [3].
We have evaluated data of 21 T-LGL lymphocytosis patients
and identified a relatively high proportion of patients with
arthropathy, also reported by some authors [3,10,19,20]. Nine
patients had RA and neutropenia and some also had splenom-
egaly and were diagnosed as FS, whereas 2 other patients
showed milder non-erosive unclassified arthritis. Our FS
patients presented a spectrum of T-LGL expansions.
It is difficult to differentiate between T-LGL leukemia and reac-
tive T-LGL proliferations, especially in autoimmune diseases.
Molecular studies may establish the clonal nature of T cells but
not in all cases confirm the diagnosis of leukemia as oligo-
clonal/monoclonal proliferations of T-LGL may occur in natural
or pathologic immune responses to strong antigens in autoim-
mune diseases or viral infections such as Epstein-Barr virus
and HIV [21]. A monoclonal population of CD8+, CD57+ T
cells was found both in neutropenic and non-neutropenic
patients with RA as well as in healthy, mostly elderly individuals
[11,22-24]. All these cases represent a benign monoclonal T-
LGL proliferation rather than true T-LGL leukemia because
they are clinically asymptomatic. Moreover, diagnostic criteria
of T-LGL leukemia in the context of the LGL population volume
are still a subject of discussion. Monoclonal LGL lymphocyto-
Figure 2
Flow cytometric analyses of patient 15 with T-cell large granular lymphocyte leukemia Flow cytometric analyses of patient 15 with T-cell large granular lymphocyte leukemia. (a) CD8+CD4- leukemic cells. (b) CD3+/CD45RA+ leukemic 
cells. (c) CD2+/CD7- leukemic cells and double-stained population in the region R2 consistent with normal T lymphocytes. (d) CD5-/CD25- leuke-
mic cells and CD5+/CD25-/+ expression on normal T lymphocytes in the region R3. (e) CD7- leukemia cells express slightly weaker levels of CD43 
compared with normal CD43+higherCD7+ cells consistent with normal T lymphocytes in the region R2. (f) CD3+ population with coexistence of CD16 
antigens. (g) CD3+CD56- leukemic cells. (h) CD2+CD57- leukemic cells. CD2+CD57+-reactive T lymphocytes in the region R2. (i) Leukemic cells 
are positive for CD3 and TCRαβ. FITC, fluorescein isothiocyanate; PE, phycoerythrin; TCR, T-cell receptor.Available online http://arthritis-research.com/content/10/3/R55
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sis of greater than 2 to 5 × 109/L is required for the diagnosis
of T-LGL leukemia according to the WHO classification [6].
However, in patients with monoclonal T-LGL lymphocytosis
and leucopenia, this criterion is not useful. Expansion of LGLs
of less than 0.5 × 109/L represents reactive lymphocytosis [6],
but there are also borderline cases with T-LGL oligoclonal or
monoclonal lymphocytosis values ranging from 0.5 to 2 ×
109/L. For such cases, Dhodapkar and colleagues [10] sug-
gested the term 'T cell clonopathy of undetermined signifi-
cance' or 'monoclonal clonopathy of unclear significance'.
However, Semenzato and colleagues [25] described 9
patients with chronic monoclonal T-LGL lymphocytosis of 0.5
to 2 × 109/L with clinical and laboratory features typical for T-
LGL leukemia. Thus, they pointed out that, for T-LGL leukemia
diagnosis, the LGL count by itself is not critical but a compre-
hensive analysis of clinical, immunopathological, and molecu-
lar data is necessary. However, the border between leukemic
and reactive clonal expansions of T-LGLs is narrow because
clinical and hematologic characteristics of T-LGL leukemia are
far from typically malignant [9].
In our group of patients with arthritis, 9 presented symptoms
of FS. Three patients (patients 2, 4, and 5) fulfilled the WHO
criteria for T-LGL leukemia diagnosis with absolute LGL
lymphocytosis of greater than 2 × 109/L and monoclonal rear-
rangement of TCRB, TCRG, or TCRD genes. In the bone mar-
row, they had interstitial and intrasinusoidal linear infiltration of
T cells expressing CD3, CD8, CD57, and granzyme B
described by Morice and colleagues [26] as a typical pattern
for T-LGL leukemia. Intrasinusoidal infiltration seems to indi-
cate a leukemic nature of the disease and may occur in other
subtypes of leukemia/lymphoma [27]. Reactive lymphoid nod-
ules, reported by Osuji and colleagues [28] to be frequent in
T-LGL leukemia, were also present. In FCM, T-LGL leukemia
cells revealed abnormal expression of CD5, CD7, and CD43
antigen, which corresponds to the findings of Lundell and col-
leagues [29]. The other 6 patients with FS showed relative
LGL lymphocytosis but had absolute LGL lymphocytosis of
less than 2 × 109/L due to leucopenia.
In three of those 6 patients (patients 1, 3, and 6) with LGL lym-
phocytosis ranging from 0.9 to 1.4 × 109/L, a clearly
monoclonal rearrangement of TCRB and TCRG genes as well
as typical for T-LGL leukemia immunophenotype were found.
However, interstitial infiltration of the bone marrow was most
common. In one patient, FCM showed abnormal expression of
Figure 3
Ethidium bromide-stained polyacrylamide gel showing polymerase chain reaction products derived from TCR gene rearrangements in patients with  rheumatoid arthritis and T-cell large granular lymphocyte (T-LGL) proliferations Ethidium bromide-stained polyacrylamide gel showing polymerase chain reaction products derived from TCR gene rearrangements in patients with 
rheumatoid arthritis and T-cell large granular lymphocyte (T-LGL) proliferations. (a) Polyclonal expansion of T-LGLs in patient 10. Lane 1: TCRB 
gene rearrangement–negative, polyclonal smear (tube A); lane 2: TCRB gene rearrangement-negative, polyclonal smear (tube B); lane 3: TCRB 
gene rearrangement-negative, polyclonal smear (tube C); lane 4: standard 50 base pairs (bp); lane 5: TCRG gene rearrangement-negative, polyclo-
nal smear (tube A); lane 6: TCRG gene rearrangement-negative, polyclonal smear (tube B); and lane 7: TCRD gene rearrangement-negative, poly-
clonal smear. (b) Monoclonal expansion in polyclonal background in patient 7. Lane 1: TCRG gene rearrangement: monoclonal product 180 bp (i) in 
tube A; lane 2: TCRG gene rearrangement: monoclonal product 210 bp (ii) in polyclonal background (tube B); lane 3: TCRD gene rearrangement: 
monoclonal product 160 bp (iii); lane 4: TCRB (tube A) gene rearrangement-negative, polyclonal smear; lane 5: standard 50 bp; lane 6: TCRB (tube 
B) gene rearrangement-negative, polyclonal smear; and lane 7: TCRB (tube C) gene rearrangement-negative, polyclonal smear. (c) Monoclonal 
gene rearrangements in patient 1 with T-LGL leukemia. Lane 1: TCRB gene rearrangement-negative (tube A); lane 2: TCRB gene rearrangement-
positive, monoclonal product 250 bp (iv) in tube B; lane 3: TCRB (tube C): gene rearrangement-negative, polyclonal smear; lane 4: standard 50 bp; 
lane 5: TCRG gene rearrangement-positive, monoclonal product 230 bp (v) in tube A; lane 6: TCRG gene rearrangement-positive, monoclonal prod-
uct 180 bp (vi) in tube B; and lane 7: TCRD gene rearrangement-negative, polyclonal smear. TCR, T-cell receptor.Arthritis Research & Therapy    Vol 10 No 3    Prochorec-Sobieszek et al.
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one T-cell antigen. The question is whether these cases
should be diagnosed as true T-LGL leukemia or as a T-cell
clonopathy of unclear significance associated with FS.
Our patient 7 displayed features of monoclonal transformation
of polyclonal LGLs. In PCR analysis, apart from monoclonal
TCRD gene rearrangement, a weak monoclonal product in the
Vγ9, Vγ11-Jγ region among polyclonal background was found.
Abundant interstitial infiltrates of T cells were observed in the
bone marrow, but without intrasinusoidal localization. This
case seems to support the hypothesis that T-LGL leukemia
may develop from polyclonal or oligoclonal expansions [30]
and correlates with the report of Langerak and colleagues
[31], who found a single dominant and several weak additional
gene products in β-chain variable region (Vβ) transcripts in
numerous T-LGL leukemia cases.
Two patients (patients 10 and 11) with no rearrangement of
TCR genes may serve as examples of autoimmune-disease-
related, polyclonal, reactive, chronic proliferation of LGL lym-
phocytes. In these two cases, the pattern of bone marrow infil-
tration and FCM analysis were consistent with reactive T-LGL
lymphocytosis [26,29]. T-LGLs were dispersed in the bone
marrow and they did not lose any pan-T-cell antigens in FCM.
As in other reports [29], FCM analysis of all of our cases with
clonal rearrangement of TCR genes showed normal reactive
peripheral blood CD57+ T lymphocytes with no pan-T-cell anti-
gen abnormalities in addition to a population of CD57+ T-LGL
leukemia cells. It is conceivable that this population of cells
may represent precursors of T-LGL leukemia.
The clinical course of 9 patients with FS, irrespective of T-LGL
absolute count and their clonality, was similar, with neutrope-
nia being the most common presentation, and remained indo-
lent for 1 to 7 years of follow-up. They were treated with
immunomodulatory agents exclusively, and 2 patients had par-
tial hematologic responses.
The described group of patients represents a spectrum of T-
LGL proliferations and supports the hypothesis that mono-
clonal expansion of LGLs with features of T-LGL leukemia may
result from the transformation of initially stable and benign pol-
yclonal or oligoclonal proliferation of these lymphocytes [30].
This proliferation may be a consequence of the disregulated
reaction of the immune system to viral or auto-antigens asso-
ciated with autoimmune processes [30,32]. There are similar-
ities in immunogenetic profile between T-LGL leukemia and
autoimmune diseases [32]. Moreover, molecular analysis
revealed common motifs in the TCRB genes in T-LGL prolifer-
ations, suggesting a potential role of antigenic stimulation in
the clonal evolution of the disease [33-35]. Unfortunately, the
triggering antigens and genetic events that cause neoplastic
transformation remain unknown. Bowman and colleagues [11]
examined two groups of patients with FS, without and with
clonal proliferation of T-LGLs, but no continuous distributions
of T-LGLs in these two groups were observed. Recently, Lang-
erak and colleagues [4] and Sandberg and colleagues [36]
have shown a continuous spectrum of T-LGL proliferations
using sensitive PCR techniques.
It is worth emphasizing that, in 4 of our patients, IGKV and
IGLV gene rearrangements were detected in PCR analysis.
Trephine biopsy examination showed a nearly normal number
of B lymphocytes dispersed and/or localized in lymphoid
nodules with the pattern and phenotype indicative of their
reactive nature. This phenomenon most probably is due to
chronic antigen stimulation in autoimmune disease [37]. It can
also correspond to crosslineage light-chain gene rearrange-
ments. None of our patients developed a B-cell lymphoma dur-
ing follow-up.
Most of our patients had long-lasting RA at the time of diagno-
sis of T-LGL leukemia, but 2 patients showed milder non-ero-
sive unclassified arthritis resembling RA. Similar findings had
been reported by Snowden and colleagues [3]. Interestingly,
these 2 patients had similar clinical features: T-LGL absolute
count of less than 2 × 109/L due to leucopenia, severe neutro-
penia, recurrent infections, skin lesions, splenomegaly, and
monoclonal rearrangements of TCRB genes. Bone marrow
infiltration was typical for T-LGL leukemia, but T-LGL cells had
the unusual phenotype (CD4+). In one of these patients,
arthropathy appeared after 17 years of hematological abnor-
malities, which indicates that T-LGL expansion may also pre-
cede inflammatory arthropathy and may be responsible for the
development of immunological abnormalities [8].
TCRαβ+/CD4+ T-LGL lymphocytosis is a rare subgroup of
monoclonal LGL lymphoproliferations and usually is character-
istic of a more indolent clinical course [35].
Patients with T-LGL leukemia with or without arthropathy
share many similarities. Arthritis and T-LGL leukemia patients
more often had leucopenia and splenomegaly and a higher
incidence of specific autoantibodies as compared with those
without arthropathy. The two groups showed a similar his-
topathological pattern and immunophenotype of bone marrow
infiltration. They also had similar molecular and genetic charac-
teristics with the most frequent rearrangements of Vβ-Jβ1, Jβ2
and Vγ If Vγ10-J regions of TCR genes and normal karyotype. In
other studies, FCM analysis of the Vβ TCR repertoire in T-LGL
leukemia cases did not reveal the preferential use of any spe-
cific Vβ gene [29,30,38]. Davey and colleagues [20] reported
that rearrangement of Vβ-6 genes occurred only in patients
with T-LGL leukemias associated with RA, although no unique
patterns of junctional sequence rearrangement were seen for
patients with T-LGL leukemia with and without arthritis.
Cytopenias (especially neutropenia) that appear in the course
of RA-associated T-LGL lymphocytosis are the result of
humoral and cellular immune mechanisms [7]. Immune com-Available online http://arthritis-research.com/content/10/3/R55
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plexes or antibodies to neutrophil antigens may induce apop-
tosis of neutrophils in patients with FS [39]. Compensatory
granulocytic hyperplasia with left-shifted maturation is
observed in bone marrow as the consequence of excessive
peripheral destruction of mature granulocytes [7]. In the
described group of patients, only two with FS (one with poly-
clonal LGL lymphocytosis, the other with T-LGL leukemia) had
hypercellular bone marrow with increased granulocyte precur-
sor count and left-shifted maturation, but no antyneutrophil
antibodies were present. The majority of our patients with T-
LGL leukemia with and without RA showed a decreased or
normal number of granulocyte precursor count in the bone
marrow with left-shifted maturation. There is a hypothesis that
T-LGL leukemia cells may inhibit proliferation and differentia-
tion of granulocytes in the mechanisms of Fas-mediated apop-
tosis of myeloid precursors and this could be the explanation
of granulocyte hypoplasia and paucity of mature forms in the
bone marrow [7]. Effector cytotoxic T cells as well as T-LGL
leukemia cells express Fas ligand, a member of the tumor
necrosis factor family, which can bind Fas and initiate apopto-
sis in the target cells through this pathway [40]. It is known that
progenitor cells (CD34+) in the bone marrow may express Fas
in response to tumor necrosis factor-alpha (TNF-α) and inter-
feron-gamma (INF-γ) in vitro [41] and cytotoxic T lymphocytes
in T-LGL leukemia may spontaneously produce INF-γ and TNF-
α after stimulation [42].
Conclusion
RA and neutropenia patients represented a continuous spec-
trum of T-LGL proliferations, although monoclonal expansions
were most frequently observed. Arthritis and T-LGL leukemia
patients more often had leucopenia and splenomegaly and a
higher incidence of specific autoantibodies as compared with
those without arthropathy. The histopathological pattern and
immunophenotype of bone marrow infiltration, molecular and
genetic characteristics, as well as indolent clinical course
were similar in T-LGL leukemia patients, with and without
arthritis. Further studies involving patients with RA and T-LGL
proliferations may provide important data for a better under-
standing of RA pathogenesis.
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